| abstract |
The present invention is generally directed to compositions and methods for the diagnosis, treatment, and prevention of lupus nephritis (LN), to the identification of novel therapeutic agents for LN, and to the creation of cell lines and animal models for studying the pathogenesis of the disease. The present invention is based on the discovery of transcribed polynucleotides that are either over-expressed or under-expressed in animals that develop lupus or are pre-disposed to lupus. |